Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022) ; volume:79 ; number:9 ; day:14 ; month:7 ; year:2023 ; pages:1239-1248 ; date:9.2023
European journal of clinical pharmacology ; 79, Heft 9 (14.7.2023), 1239-1248, 9.2023
- Urheber
-
Lin, Jialing
Pearson, Sallie-Anne
Greenfield, Jerry R.
Park, Kyeong Hye
Havard, Alys
Brieger, David
Day, Richard O.
Falster, Michael O.
Oliveira Costa, Juliana de
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00228-023-03539-8
- URN
-
urn:nbn:de:101:1-2023110412590023848230
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lin, Jialing
- Pearson, Sallie-Anne
- Greenfield, Jerry R.
- Park, Kyeong Hye
- Havard, Alys
- Brieger, David
- Day, Richard O.
- Falster, Michael O.
- Oliveira Costa, Juliana de
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors